| Literature DB >> 32185892 |
Julia Sanchez-Garrido1, Sabrina L Slater1, Abigail Clements1, Avinash R Shenoy2, Gad Frankel1.
Abstract
Enteric pathogen-host interactions occur at multiple interfaces, including the intestinal epithelium and deeper organs of the immune system. Microbial ligands and activities are detected by host sensors that elicit a range of immune responses. Membrane-bound toll-like receptors and cytosolic inflammasome pathways are key signal transducers that trigger the production of pro-inflammatory molecules, such as cytokines and chemokines, and regulate cell death in response to infection. In recent years, the inflammasomes have emerged as a key frontier in the tussle between bacterial pathogens and the host. Inflammasomes are complexes that activate caspase-1 and are regulated by related caspases, such as caspase-11, -4, -5 and -8. Importantly, enteric bacterial pathogens can actively engage or evade inflammasome signalling systems. Extracellular, vacuolar and cytosolic bacteria have developed divergent strategies to subvert inflammasomes. While some pathogens take advantage of inflammasome activation (e.g. Listeria monocytogenes, Helicobacter pylori), others (e.g. E. coli, Salmonella, Shigella, Yersinia sp.) deploy a range of virulence factors, mainly type 3 secretion system effectors, that subvert or inhibit inflammasomes. In this review we focus on inflammasome pathways and their immune functions, and discuss how enteric bacterial pathogens interact with them. These studies have not only shed light on inflammasome-mediated immunity, but also the exciting area of mammalian cytosolic immune surveillance.Entities:
Keywords: zzm321990E. coli; zzm321990Listeria monocytogenes; zzm321990Salmonella; zzm321990Shigella; zzm321990Yersinia; inflammasomes
Mesh:
Substances:
Year: 2020 PMID: 32185892 PMCID: PMC7154749 DOI: 10.1111/cmi.13184
Source DB: PubMed Journal: Cell Microbiol ISSN: 1462-5814 Impact factor: 3.715
Figure 1Inflammasome‐forming sensors and their known activators. Inflammasomes are multiprotein complexes that function as platforms to activate caspase‐1. Some inflammasome sensors, such as NLRP3, PYRIN and NLRP1B, are activated following perturbations of cellular homeostasis triggered by damage or microbial associated molecular patterns. For example, mitochondrial or lysosomal disruption will lead to NLRP3 activation, while inhibition of host Rho‐GTPases will allow PYRIN inflammasome assembly and degradation of the NLRP1B N‐terminal will lead to nucleation of the free CARD‐containing NLRP1B C‐terminus. Other inflammasome sensors, exemplified by AIM2, NAIP‐NLRC4 and caspase‐11 (caspase‐4 and 5 in humans), are activated in response to direct detection of their ligands: DNA is recognised by the AIM2 HIN200 domain, NAIP proteins bind flagellin and type 3 secretion system (T3SS) needles and rods, and the caspase‐11 CARD domain interacts with LPS. Active caspase‐11/4/5 cleaves Gasdermin D (GSDMD), leading to pore formation and subsequent potassium efflux, which can trigger non‐canonical activation of the NLRP3 inflammasome, and pyroptosis. NLRP6 functions as a direct sensor of lipoteichoic acid (LTA), but can also be activated by changes in the microbiota and has additionally been shown to perform inflammasome‐independent functions. *Human NLRP1 has an N‐terminal PYD domain. Domain compositions are colour coded and abbreviated as follows: CARD, caspase‐activation and recruitment domain; p20 and p10, large and small catalytic subunits; PYD, pyrin domain; NOD, nucleotide binding and oligomerisation domain; LRR, leucine rich repeat; BIR, baculovirus inhibitor of apoptosis domain; HIN200, haematopoietic expression, interferon inducible, nuclear localised (HIN) DNA binding domain of ∼200 residues; C‐C, coiled‐coil; FIIND, function to find domain
Figure 2Enteric pathogens can activate multiple inflammasome pathways. Schematics from (a) to (f) show how various enteric pathogens stimulate the assembly and activation of different inflammasomes, focussing on the activating signal (signal 2). Downstream consequences of inflammasome activation shown in Figure 1, that is Gasdermin D cleavage, pore formation and pyroptosis, caspase‐1‐mediated cleavage of pro‐IL‐1β and pro‐IL‐18 into their active forms and the release of these pro‐inflammatory cytokines together with alarmins, are not depicted for simplicity. A/E pathogens (such as Enteropathogenic and Enterohaemorrhagic E. coli, EPEC and EHEC) (a), Helicobacter pylori (e) and Yersinia (f) are mainly extracellular pathogens, while Salmonella survives intracellularly in Salmonella containing vacuoles (SCVs) (b) and Shigella (c) and (d) are cytosolic bacteria that escape the vacuoles and can move from cell to cell via manipulation of the host actin cytoskeleton. Host proteins are featured in greyscale to emphasise the role of bacterial factors. See text for further information on the mechanisms employed by these pathogens to evade or subvert inflammasomes. OMV, outer membrane vesicle; Stx, Shiga toxin; Tir, translocated intimin receptor; GBP1, guanylate binding protein 1; GLMN, glomulin; LLO, listeriolysin; LTA, lipoteichoic acid; VacA, vacuolating cytotoxin A; CagA, cytotoxin‐associated gene A; ROS, reactive oxygen species; KD, kinase domain; RHIM, RIP (receptor‐interacting serine/threonine‐protein) homotypic interaction motif; DD, death domain; Yop, Yersinia outer protein
Enteric pathogens and the inflammasomes: activation and inhibition
| Pathogen | Inflammasome | Virulence factor | Effect | References |
|---|---|---|---|---|
|
| CASP4/Casp11 | LPS (T3SS‐independent) (EPEC/EHEC) | Activator | (Knodler et al., |
| CASP4 → NLRP3 | Stx (EHEC) | (Lee et al., | ||
| Tir and LPS (T3SS‐dependent) (EPEC) | (Goddard et al., | |||
| NLRP3 | Haemolysin EhxA (EHEC) | (Zhang et al., | ||
| Nlrp3 | RNA:DNA (EHEC) | (Vanaja et al., | ||
| Naip2‐Nlrc4 | EscI (T3SS rod; EPEC/EHEC), EprJ (ETT2 rod; EHEC) | (Miao, Mao, et al., | ||
| NAIP‐NLRC4 | EprI (ETT2 needle; EHEC) | (Yang et al., | ||
| NLRP3 | NleA/EspI (EPEC) | Inhibitor | (Yen et al., | |
| CASP4/Casp11 | NleF (EPEC) | (Blasche et al., | ||
|
| NAIP‐NLRC4 | Flagellin | Activator | (Broz, Newton, et al., |
| NAIP‐NLRC4 | PrgJ (inner SPI‐1 T3SS rod) | (Kofoed & Vance, | ||
| NAIP‐NLRC4 | PrgI (SPI‐1 T3SS needle) | (Zhao et al., | ||
| CASP4/Casp11 → NLRP3/Nlrp3 | LPS | (Shenoy et al., | ||
| CASP4/Casp11 | LPS | (Knodler et al., | ||
| Nlrp3 | Curli fibres | (Rapsinski et al., | ||
| ? (↓NADH, ↑mitoROS)* | (Sanman et al., | |||
| Nlrp3?* | SlrP | Inhibitor | (Rao et al., | |
| Casp11 → Nlrp3 | Aconitase | (Wynosky‐Dolfi et al., | ||
|
| CASP4/Casp11 | LPS | Activator | (Kobayashi et al., |
| Naip2‐Nlrc4 | MxiI (T3SS rod) | (Miao, Mao, et al., | ||
| Naip‐NLRC4 | MxiH (T3SS needle) | (Yang et al., | ||
| NLRC4/Nlrc4? | IpaB | (Senerovic et al., | ||
| NLRP3/Nlrp3 & NLRC4/Nlrc4 | IpaH7.8 | (Suzuki, Mimuro, et al., | ||
| Nlrp1b | IpaH7.8 | (Neiman‐Zenevich et al., | ||
| CASP4 | OspC3 | Inhibitor | (Kobayashi et al., | |
|
| NLRP3/Nlrp3 | Listeriolysin (LLO) | Activator | (Zwaferink, Stockinger, Hazemi, Lemmens‐Gruber, & Decker, |
| Nlrp3 | p60 | (Schmidt & Lenz, | ||
| RNA | (Kanneganti et al., | |||
| Aim2 | dsDNA | (Kim et al., | ||
| Naip‐Nlrc4 | Flagellin | (Warren, Mao, Rodriguez, Miao, & Aderem, | ||
| Nlrp6‐Casp4 | Lipoteichoic acid (LTA) | (Meixenberger et al., | ||
| CASP4 | ?* | (Hara et al., | ||
| Nlrp1b | Host cell energy stress?* | (Neiman‐Zenevich et al., | ||
|
| Nlrc4?* (in vivo) | YopB, YopD ( | Activator | (Brodsky et al., |
| Nlrp3 | YopB, YopD ( | (Brodsky et al., | ||
| CASP4/Casp11 | LPS ( | (Casson et al., | ||
| Rip1‐Casp8‐Casp1 | YopJ ( | (Philip et al., | ||
| Pyrin | YopE, YopT ( | (Chung et al., | ||
| Naip5‐Nlrc4 | Flagellin ( | (Matusiak et al., | ||
| Nlrp3 | YopK ( | Inhibitor | (Brodsky et al., | |
| Pyrin/ Casp1 | YopM ( | (LaRock & Cookson, | ||
| NLRP3/Nlrp3 | YopH, YopE ( | (Schotte et al., |
Notes: Bacterial components and infection‐mediated alterations of host cells that lead to inflammasome activation are shaded in orange; inflammasome inhibitors are shown shaded in blue. Indirect inhibitors of NLRP3, for example via inhibition of NF‐κB signalling, are not featured in the table (refer to text). H. pylori‐encoded direct activators/inhibitors of inflammasome activation not well defined, and thus the pathogen is not included. When the human inflammasome genes have been involved, these are shown in uppercase (e.g. NLRP3); mouse genes are shown in lowercase except the first letter (e.g. Nlrp3). * indicates when the study does not define which inflammasome is involved or what the bacterial activating signal/factor is.
Abbreviations: mitoROS, mitochondrial reactive oxygen species; Ye, Yersinia enterocolitica; Yps, Yersinia pseudotuberculosis.